Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Taps Avant’s Phase II Brain Cancer Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Therapeutic vaccine is a “beautiful” match with temozolomide, Avant CEO tells “The Pink Sheet” DAILY.
Advertisement

Related Content

Pfizer Axes Deal For Brain Cancer Vaccine, Leaves Partner Celldex In the Lurch
Pfizer Axes Deal For Brain Cancer Vaccine, Leaves Partner Celldex In the Lurch
Cancer Vaccine Makers Capitalize On Provenge Fanfare At ASCO
Cancer Vaccine Makers Capitalize On Provenge Fanfare At ASCO
Avant’s Brain Cancer Vaccine Passes Phase II
Avant’s Brain Cancer Vaccine Passes Phase II
Weak Result Stops Pfizer’s Tremelimumab Phase III Trial
Weak Result Stops Pfizer’s Tremelimumab Phase III Trial

Topics

Advertisement
UsernamePublicRestriction

Register

PS067589

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel